A new study suggests that the drug Remdesivir - if it is given early in an illness with coronavirus - can lower mortality significantly.
in Fact, up to 80 per cent.
It is ground-breaking results and for the first time, you have been able to demonstrate an effect of treatment against the coronavirus, " says Jens Lundgren, professor of communicable diseases at Rigshospitalet and leader of the european part of the study.
the Study shows that if we treat the infection early and before it has caused serious organ damage, there seems to be a significant advantage.
Remdesivir was originally developed to treat hepatitis and ebola.
the Medication is not particularly effective late in a course with the coronavirus. But if it be right, when a pneumonia has hit, there is a great difference.
- It is in line with what we had expected. But we knew it not, for there has not been a treatment for coronaviruses. It is the first time we can demonstrate an effect, he says.
According to the newspaper, Politiken, shows the study, that four out of 222 patients who were treated with Remdesivir, died two weeks after – as against 19 patients out of 199 who got the placebo instead.
Denmark is even with in the experiment. The study includes the 1063 patients around the world with moderate to severe disease due to coronavirus. 42 of them are danes.
Although there must be many reservations, and that there is talk about the preliminary data, " says Jens Lundgren, that it changes the whole way we approach the treatment of patients with coronavirus.
Yet, there are, however, uncertainties about the side effects of the drug, which has not yet been approved.
- Whether the substance itself has a side effect, especially in the liver and kidney, as we know from other studies and patient groups, that it might have, need to be further analysed.
But overall, when you balance the pros and cons, we can see that it works, if one starts early, he says.
the Study is still in progress and is expected to be completed at the end of June or beginning of July.